Generali Asset Management SPA SGR purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 6,917 shares of the life sciences company's stock, valued at approximately $924,000.
A number of other large investors have also added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its stake in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in Illumina during the 4th quarter valued at approximately $32,000. Assetmark Inc. increased its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the 4th quarter valued at approximately $45,000. Finally, TD Private Client Wealth LLC boosted its stake in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after buying an additional 141 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Trading Down 0.6 %
Shares of NASDAQ ILMN traded down $0.49 during mid-day trading on Tuesday, hitting $87.53. 2,839,519 shares of the company traded hands, compared to its average volume of 2,096,306. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of -11.40, a PEG ratio of 1.60 and a beta of 1.17. The business has a 50 day moving average of $107.08 and a two-hundred day moving average of $127.97.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ILMN has been the topic of several recent analyst reports. Morgan Stanley cut their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. TD Cowen lowered shares of Illumina from a "buy" rating to a "hold" rating and cut their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Piper Sandler lifted their price target on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Guggenheim reduced their target price on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada lowered their price target on Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $140.90.
View Our Latest Stock Analysis on ILMN
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
